Omsal (Tamsulosin Hydrochloride)

Tamsulosin Hydrochloride, the active ingredient in Omsal, is an alpha‑1 adrenergic antagonist presented as a tablet for oral use. It relaxes smooth muscle in the prostate and bladder neck to improve urine flow in men with benign prostatic hyperplasia.

GNH USA supplies Omsal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Tamsulosin is indicated for conditions affecting the lower urinary tract that involve smooth‑muscle tone.

- Benign prostatic hyperplasia (BPH): improves urinary flow and reduces symptoms such as urgency and nocturia. - Chronic prostatitis: may alleviate associated urinary discomfort. - Post‑void residual reduction: helps lower residual urine volume after voiding.

Adverse reactions to tamsulosin are generally mild to moderate and vary among individuals.

Common Side Effects: - Dizziness or light‑headedness, especially after the first dose. - Abnormal ejaculation (retrograde or reduced volume). - Nasal congestion or runny nose. - Headache. - Fatigue.

Serious or Rare Side Effects: - Severe hypotension or syncope. - Priapism (prolonged erection). - Allergic reactions such as rash, itching, or swelling. - Angioedema affecting face or throat. - Persistent urinary retention. - Cardiac arrhythmias (rare).

Before initiating therapy, patients should be evaluated for cardiovascular status and potential drug interactions.

- Assess blood pressure: monitor for orthostatic changes after the first dose. - Review concomitant medications: avoid concurrent use with potent CYP3A4 inhibitors. - Evaluate renal and hepatic function: dose adjustment may be needed in severe impairment. - Counsel on dizziness: advise patients to rise slowly from sitting or lying positions. - Pregnancy and lactation: contraindicated in women; safety not established. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Tamsulosin may interact with several drug classes, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase tamsulosin plasma levels. - Alpha‑blockers used for hypertension: combined effect can cause marked hypotension.

Moderate Interactions (Monitor Closely): - Phosphodiesterase‑5 inhibitors (e.g., sildenafil): may enhance risk of hypotension. - Antihistamines and other sedatives: can increase dizziness. - Diuretics: may exacerbate orthostatic blood‑pressure changes. - NSAIDs: may affect renal function when combined with tamsulosin.